Opinion|Videos|August 23, 2024
Role of Biologics in Dermatological Care
A key opinion leader examines how the introduction of biologic therapies revolutionized atopic dermatitis treatment, addressing strategies to manage patients' concerns about needles and injections.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How have the emergence of biologics changed the treatment landscape of these diseases caused by an overactive immune response?
- How do you approach presenting monoclonal antibody treatments to patients or caregivers who have an apprehension of needles or injections? What strategies do you use to alleviate their concerns and gain their trust in proceeding with this preferred treatment option?
Advertisement
Related to this article
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
3
GLP-1 Receptor Agonists Cut Ascites, Mortality in MASH
4
Hepatitis A Vaccine Prevents 96% of Infections Given Before Exposure
5